Decoy Therapeutics Inc. (DCOY)
| Market Cap | 740.29K -73.8% |
| Revenue (ttm) | 227,629 |
| Net Income | -14.45M |
| EPS | -40.40 |
| Shares Out | 655.19K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,679 |
| Open | 1.136 |
| Previous Close | 1.120 |
| Day's Range | 1.120 - 1.136 |
| 52-Week Range | 0.900 - 39.715 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About DCOY
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design α-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting ... [Read more]
Financial Performance
Financial StatementsNews
Decoy Therapeutics Provides Third Quarter 2026 Business Update
Lead pan-coronavirus program expected to file CTA/IND in 2H 2027 Optimized lead candidate shows potential for once-weekly dosing in preclinical studies Cash on balance sheet of $8.1 million at Septemb...
Decoy Therapeutics registers to sell 2.37M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.37M shares of common stock. The company is not selling any…
Decoy Therapeutics Registration statement: Registration filing
Decoy Therapeutics filed a registration statement on October 7, 2026, providing details about a securities offering with the SEC.
Decoy Therapeutics to Present at The Small Cap Showcase
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York
Decoy Therapeutics’ human coronaviruses candidate shows positive PK data
Decoy Therapeutics (DCOY) announced preclinical pharmacokinetic, or PK, data supporting once-weekly intranasal administration for its lead program, DCOY-CoV. Results demonstrate that a single intranas...
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Once-Weekly Intranasal Potential : Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addres...
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Compa...
Why Is Penny Stock Decoy Therapeutics (DCOY) Up 48% Today?
Decoy Therapeutics stock was up 48.05% on Tuesday after the company said it plans to explore Designable Multi-Antivirals for additional candidates.
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of ...
Decoy Therapeutics to explore pan-filovirus program via FDA Animal Rule pathway
Decoy Therapeutics (DCOY) announced a corporate strategy to explore its Designable Multi-Antivirals, or D-MAVs, for additional candidates, including a pan-filovirus program along the FDA Animal Rule p...
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRN...
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc...
Decoy Therapeutics Quarterly report: Q2 2026
Decoy Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the de...
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus
Decoy Therapeutics (DCOY) announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building ...
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Thera...
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineere...
Decoy Therapeutics registers to sell 3.77M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.77M shares of common stock. The company is not selling any…
Decoy Therapeutics Registration statement: Registration filing
Decoy Therapeutics filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?
Decoy Therapeutics stock rallied on Monday alongside news of new funding for the company.
Decoy Therapeutics Inc trading resumes
09:36 EDT Decoy Therapeutics (DCOY) Inc trading resumes
Decoy Therapeutics Inc trading halted, volatility trading pause
09:31 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause